Akèy › Kansè pwostat › Maryland
Etid klinik pou Kansè pwostat nan Maryland
65 etid pou Kansè pwostat ap chèche patisipan nan sit nan Maryland.
Vil nan Maryland
Tèks ofisyèl etid la (Anglè)
Imaging Studies to Check the Local Response of Prostate Cancer to Radiation Therapy
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteEtid obsèvasyon
Laj 18 a 120 · Gason · Mizajou Oct 2, 2026 · NCT01834001IL-15 Superagonist With or Without Vaccine in Biochemically Recurrent Prostate Cancer After Previous Stereotactic Body Radiation Therapy
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteFaz 2
Laj 18 a 120 · Gason · Mizajou Oct 2, 2026 · NCT07686380Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial
- Maryland Proton Treatment Center, Baltimore
- University of Maryland/Greenebaum Cancer Center, Baltimore
- UM Upper Chesapeake Medical Center, Bel Air
- ak 3 plis
Ap rekriteFaz 3
Laj 18 ak plis · Gason · Mizajou Oct 2, 2026 · NCT07200830Collection of Blood From Patients With Prostate Cancer
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Gason · Mizajou Oct 2, 2026 · NCT00923221Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Mercy Medical Center, Baltimore
- Sinai Hospital of Baltimore, Baltimore
- MedStar Franklin Square Medical Center/Weinberg Cancer Institute, Baltimore
- ak 10 plis
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 40 a 75 · Tout sèks · Mizajou Oct 2, 2026 · NCT05334069Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteEtid obsèvasyon
Laj 3 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT01441089A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Johns Hopkins University, Baltimore
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT06172478Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- National Institutes of Health Clinical Center, Bethesda
- FMH James M Stockman Cancer Institute, Frederick
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT03866382Collection of Blood From Patients With Cancer
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT00034216Precision-Based Genomics in Prostate Cancer
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteEtid obsèvasyon
Laj 18 a 120 · Gason · Mizajou Sep 28, 2026 · NCT04706663Prostate Cancer Risk Identification in a Multi-Ethnic Cohort: a Prospective US-based Multi-center Validation Study of Proclarix
- Chesapeake Urology Associates, Hanover
- Chesapeake Urology Associates, Towson
Ap rekriteEtid obsèvasyon
Laj 40 a 75 · Gason · Mizajou Sep 28, 2026 · NCT07543757Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer
- University of Maryland, Greenebaum Comprehensive Cancer Center, Baltimore
Ap rekriteFaz 1
Laj 18 ak plis · Gason · Mizajou Sep 25, 2026 · NCT06801236A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
- Baltimore Veterans Affairs Medical Center ( Site 0069), Baltimore
- Greenebaum Comprehensive Cancer Center ( Site 0049), Baltimore
- Chesapeake Urology ( Site 0009), Towson
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06136650Prospective Monitoring of Subjects With Biochemically Recurrent Prostate Cancer Using 18FDCFPyL
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Gason · Mizajou Sep 22, 2026 · NCT05588128Care of the Prostate Cancer Patient and Prospective Procurement of Prostate Cancer Tissue
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Gason · Mizajou Sep 22, 2026 · NCT02594202A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
- University of Maryland Greenebaum Cancer Center, Baltimore
- Johns Hopkins Hospital Sidney Kimmell Comprehensive Cancer Center, Baltimore
Ap rekriteFaz 3
Laj 18 ak plis · Gason · Mizajou Sep 22, 2026 · NCT07213674A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
- Research Site, Towson
Ap rekriteFaz 3
Laj 18 ak plis · Gason · Mizajou Sep 18, 2026 · NCT06952803A Phase II Study Evaluating T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination With the Immunocytokine PDS01ADC in Localized High and Intermediate Risk Prostate Cancer Treated With Androgen Deprivation Therapy
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteFaz 2
Laj 18 ak plis · Gason · Mizajou Sep 18, 2026 · NCT05361798Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteFaz 2
Laj 18 a 120 · Gason · Mizajou Sep 17, 2026 · NCT05616650A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
- Greenebaum Comprehensive Cancer Center ( Site 0021), Baltimore
Ap rekriteFaz 3
Laj 18 ak plis · Gason · Mizajou Sep 17, 2026 · NCT06925737PROMISE Registry: A Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment Effectiveness
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Gason · Mizajou Sep 15, 2026 · NCT04995198A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec
- Chesapeake Urology Research Associates, Towson
Ap rekriteFaz 2
Laj 18 ak plis · Gason · Mizajou Sep 15, 2026 · NCT07332000Sacral Neuromodulation for Male Overactive Bladder (MOAB)
- Anne Arundel Urology, Annapolis
Ap rekrite
Laj 18 ak plis · Gason · Mizajou Sep 14, 2026 · NCT06511141Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
- Maryland Proton Treatment Center, Baltimore
- University of Maryland/Greenebaum Cancer Center, Baltimore
- Veterans Administration Medical Center-Baltimore, Baltimore
- ak 7 plis
Ap rekriteFaz 3
Laj 18 ak plis · Gason · Mizajou Sep 10, 2026 · NCT05946213Profiling of Radiological Factors in Treatment and Outcomes in Prostate Cancer
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Gason · Mizajou Sep 8, 2026 · NCT03354416Enzalutamide and PDS01ADC in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering Therapy
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteFaz 2
Laj 18 a 120 · Gason · Mizajou Sep 3, 2026 · NCT06096870Patient Navigation Program to Improve Clinical Trial Enrollment in Cancer Patients
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Sep 3, 2026 · NCT06138067Men at High Genetic Risk for Prostate Cancer
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteEtid obsèvasyon
Laj 30 a 75 · Gason · Mizajou Sep 3, 2026 · NCT03805919A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteFaz 1/2
Laj 18 a 110 · Gason · Mizajou Sep 3, 2026 · NCT04633252The Vanguard Study: Testing a New Way to Screen for Cancer
- Walter Reed National Military Medical Center, Bethesda
Ap rekriteVolontè an sante akeyi
Laj 45 a 75 · Tout sèks · Mizajou Sep 2, 2026 · NCT06995898Multiparametric Magnetic Resonance Imaging of the Prostate to Assess Disease Progression and Genomics in Patients Undergoing Active Surveillance for Prostate Cancer
- National Institutes of Health Clinical Center, Bethesda
Ap rekrite
Laj 18 ak plis · Gason · Mizajou Aug 27, 2026 · NCT04692675Transrectal Ultrasound Robot-Assisted Prostate Biopsy
- Johns Hopkins Hospital, Baltimore
Ap rekrite
Laj 45 a 75 · Gason · Mizajou Aug 26, 2026 · NCT02871726Study of Oral MRT-2359 With Apalutamide in Prostate Cancer
- University of Maryland Greenebaum Cancer Center, Baltimore
Ap rekriteFaz 2
Laj 18 ak plis · Gason · Mizajou Aug 24, 2026 · NCT07745361A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC
- Johns Hopkins Hospital, Baltimore
Ap rekriteFaz 1/2
Laj 18 ak plis · Gason · Mizajou Aug 20, 2026 · NCT06785636Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
- Suburban Hospital, Bethesda
Ap rekriteFaz 3
Laj 18 ak plis · Gason · Mizajou Aug 19, 2026 · NCT04423211FOG-001 in Locally Advanced or Metastatic Solid Tumors
- Johns Hopkins University, The Sidney Kimmel Comprehensive Cancer Center, Baltimore
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 17, 2026 · NCT05919264Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
- University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore
Ap rekriteFaz 1
Laj 18 a 100 · Gason · Mizajou Aug 13, 2026 · NCT05519449Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic Castration-resistant Prostate Cancer
- Johns Hopkins University, Baltimore
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Gason · Mizajou Aug 12, 2026 · NCT04489719Surface Electrical Stimulation for Urinary Incontinence in Men Treated for Prostate Cancer
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteFaz 2
Laj 18 a 120 · Gason · Mizajou Jul 24, 2026 · NCT06161506Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
- Christiana Care - Union Hospital, Elkton
Ap rekriteFaz 3
Laj 18 ak plis · Gason · Mizajou Jul 14, 2026 · NCT06592924Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.